Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U

Next Previous
Trial Profile

A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms HOVON 130 NHL

Most Recent Events

  • 07 Apr 2022 This trial has been completed in Belgium (Date of the global end of the trial : 31-Jan-2022), according to European Clinical Trials Database record.
  • 14 Dec 2021 Results (N 323) HOVON-84, HOVON-130, and PETAL trials investigating ability to predict outcome in DLBCL can be improved by combining different clinical, radiomics and genetic features presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 17 Jun 2021 Results of HOVON-130 (n=80 MYC+ DLBCL patients), and HOVON-84 (n=126 MYC- DLBCL patients) study assessing 18F-FDG PET/CT response in DLBCL patients with MYC rearrangements compared to the response patterns of DLBCL patients without MYC rearrangements, presented at the 26th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top